{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:27:32Z","timestamp":1792218452031,"version":"4.4.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan KK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.lungcan.2026.109432","type":"journal-article","created":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T20:58:27Z","timestamp":1777841907000},"page":"109432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Phase II study of ramucirumab plus erlotinib for treatment-na\u00efve patients with EGFR-mutant non-squamous non-small cell lung cancer and pleural effusion (RELAY-Effusion)"],"prefix":"10.1016","volume":"217","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7696-2391","authenticated-orcid":false,"given":"Hiroyasu","family":"Kaneda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4598-220X","authenticated-orcid":false,"given":"Motoko","family":"Tachihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5983-3531","authenticated-orcid":false,"given":"Yukihiro","family":"Toi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Kuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiki","family":"Ichihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9175-3627","authenticated-orcid":false,"given":"Yasuhito","family":"Fujisaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4123-3567","authenticated-orcid":false,"given":"Takayasu","family":"Kurata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9221-8880","authenticated-orcid":false,"given":"Akihito","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2009-0210","authenticated-orcid":false,"given":"Hisashi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6945-281X","authenticated-orcid":false,"given":"Tadaaki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5595-5010","authenticated-orcid":false,"given":"Toshihide","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6354-1669","authenticated-orcid":false,"given":"Takahide","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1536-7640","authenticated-orcid":false,"given":"Ken","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Katakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3880-762X","authenticated-orcid":false,"given":"Ryota","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisako","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Shintani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109432_b0005","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1200\/JCO.21.01626","article-title":"Targeted therapies for lung cancer patients with oncogenic driver molecular alterations","volume":"40","author":"Tan","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109432_b0010","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.21037\/jtd.2019.08.61","article-title":"Differences in molecular epidemiology of lung cancer among ethnicities (asian vs","volume":"12","author":"Izumi","year":"2020","journal-title":"Caucasian), J. Thorac. Dis."},{"key":"10.1016\/j.lungcan.2026.109432_b0015","first-page":"2892","article-title":"EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)","volume":"5","author":"Midha","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109432_b0020","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1200\/JCO-25-01061","article-title":"Therapy for Stage IV non-small cell lung cancer with driver alterations: ASCO living guideline, version 2025.1","volume":"43","author":"Reuss","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109432_b0025","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"FLAURA investigators, overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109432_b0030","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"FLAURA investigators, Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109432_b0035","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"FLAURA2 investigators, Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109432_b0040","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.ccell.2021.07.005","article-title":"Bevacizumab plus erlotinib in chinese patients with untreated, EGFR-mutated, advanced NSCLC (Artemis-CTONG1509): a multicenter phase 3 study","volume":"39","author":"Zhou","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lungcan.2026.109432_b0045","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","article-title":"Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"20","author":"Saito","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2026.109432_b0050","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.cllc.2016.04.001","article-title":"Beverly: rationale and design of a randomized open-label phase III trial comparing bevacizumab plus erlotinib versus erlotinib alone as first-line treatment of patients with EGFR-mutated advanced nonsquamous non-small-cell lung cancer","volume":"17","author":"Gridelli","year":"2016","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109432_b0055","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2213-2600(17)30129-7","article-title":"BELIEF collaborative group, Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial","volume":"5","author":"Rosell","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.lungcan.2026.109432_b0060","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.annonc.2021.11.010","volume":"33","author":"Soo","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109432_b0065","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109432_b0070","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa2503001","article-title":"Overall survival with Amivantamab-Lazertinib in EGFR-mutated advanced NSCLC","volume":"393","author":"Yang","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109432_b0075","unstructured":"National Comprehensive Cancer Network (NCCN), NCCN Clinical Practice Guidelines in Oncology: Non-small Cell Lung Cancer, version 4.2026, NCCN, Plymouth Meeting, Pennsylvania, 2026. https:\/\/www.nccn.org. (Accessed March 16, 2026)."},{"key":"10.1016\/j.lungcan.2026.109432_b0080","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1200\/JCO.2013.50.5453","article-title":"Prognostic impact of minimal pleural effusion in non-small-cell lung cancer","volume":"32","author":"Ryu","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109432_b0085","first-page":"2192","article-title":"Erlotinib with or without bevacizumab as a first-line therapy for patients with advanced nonsquamous epidermal growth factor receptor-positive non-small cell lung cancer: exploratory subgroup analyses from the phase II JO25567 study, Thorac","volume":"13","author":"Hosomi","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2026.109432_b0090","first-page":"402","article-title":"Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion, Thorac","volume":"15","author":"Kiritani","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2026.109432_b0095","first-page":"304","article-title":"Presence of pleural effusion is associated with a poor prognosis in patients with epidermal growth factor receptor-mutated lung cancer receiving tyrosine kinase inhibitors as first-line treatment, Asia Pac","volume":"13","author":"Wang","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109432_b0100","article-title":"Osimertinib and bevacizumab cotreatment for untreated EGFR-mutated NSCLC with malignant pleural or pericardial effusion (SPIRAL II): a single-arm, open-label, phase 2 clinical trial","volume":"3","author":"Hibino","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.lungcan.2026.109432_b0105","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s10637-019-00808-1","article-title":"Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation","volume":"38","author":"Kawamura","year":"2020","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.lungcan.2026.109432_b0110","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.21873\/anticanres.12629","article-title":"Impact of pleural effusion on outcomes of patients receiving osimertinib for NSCLC harboring EGFR T790M","volume":"38","author":"Masuhiro","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.lungcan.2026.109432_b0115","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/00063198-200207000-00009","article-title":"Vascular endothelial growth factor: the key mediator in pleural effusion formation","volume":"8","author":"Grove","year":"2002","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.lungcan.2026.109432_b0120","first-page":"8019","article-title":"The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non\u2013small cell lung cancer (Review)","volume":"17","author":"Chen","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.lungcan.2026.109432_b0125","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jtho.2020.10.006","article-title":"Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC","volume":"16","author":"Le","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109432_b0130","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jtho.2020.11.022","article-title":"Altered regulation of HIF-1\u03b1 in naive- and drug-resistant EGFR-mutant NSCLC: implications for a vascular endothelial growth factor-dependent phenotype","volume":"16","author":"Nilsson","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109432_b0135","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1158\/1078-0432.CCR-08-2904","article-title":"Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance","volume":"15","author":"Naumov","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109432_b0140","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/S1470-2045(14)70381-X","article-title":"Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study","volume":"15","author":"Seto","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2026.109432_b0145","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1634\/theoncologist.2014-0465","article-title":"Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor","volume":"20","author":"Zhao","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.lungcan.2026.109432_b0150","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2026.109432_b0155","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","article-title":"RELAY Study investigators, Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Nakagawa","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2026.109432_b0160","doi-asserted-by":"crossref","first-page":"e492","DOI":"10.1016\/j.cllc.2019.03.002","article-title":"Phase I\/II study of osimertinib with bevacizumab in EGFR-mutated, T790M-positive patients with progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L)","volume":"20","author":"Akamatsu","year":"2019","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109432_b0165","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.jtho.2022.05.006","article-title":"Randomized phase 2 study of osimertinib plus bevacizumab versus osimertinib for untreated patients with nonsquamous NSCLC harboring EGFR mutations: WJOG9717L study","volume":"17","author":"Kenmotsu","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109432_b0170","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejca.2021.09.041","article-title":"Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT)","volume":"159","author":"Sakata","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109432_b0175","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.2217\/fon-2016-0163","article-title":"Erlotinib for Japanese patients with activating EGFR mutation-positive non-small-cell lung cancer: combined analyses from two phase II studies","volume":"12","author":"Atagi","year":"2016","journal-title":"Future Oncol."},{"key":"10.1016\/j.lungcan.2026.109432_b0180","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41392-020-0161-7","article-title":"Progression of malignant pleural effusion during the early stage of gefitinib treatment in advanced EGFR-mutant lung adenocarcinoma involving complex driver gene mutations","volume":"5","author":"Liu","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.lungcan.2026.109432_b0185","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41698-024-00609-7","article-title":"Prediction of TKI response in EGFR-mutant lung cancer patients-derived organoids using malignant pleural effusion","volume":"8","author":"Lee","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.lungcan.2026.109432_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2025.05.015","article-title":"Osimertinib as first-line treatment for patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting: updated overall survival data (OSI-FACT-OS)","volume":"26","author":"Sakata","year":"2025","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109432_b0195","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41416-020-01140-9","article-title":"FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial","volume":"124","author":"Heinemann","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109432_b0200","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1200\/JCO.24.00533","article-title":"A multicenter open-label randomized phase II study of osimertinib with and without ramucirumab in tyrosine kinase inhibitor-na\u00efve EGFR-mutant metastatic non-small cell lung cancer (RAMOSE trial)","volume":"43","author":"Le","year":"2025","journal-title":"J. Clin. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004939?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004939?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T01:15:26Z","timestamp":1781140526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226004939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":40,"alternative-id":["S0169500226004939"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109432","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II study of ramucirumab plus erlotinib for treatment-na\u00efve patients with EGFR-mutant non-squamous non-small cell lung cancer and pleural effusion (RELAY-Effusion)","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109432","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109432"}}